Effects of the Immunostimulant, Levamisole, on Opiate Withdrawal and Levels of Endogenous Opiate Alkaloids and Monoamine Neurotr
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
International Journal of Molecular Sciences Review Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? Rola El Sayed 1 , Yolla Haibe 2, Ghid Amhaz 2, Youssef Bouferraa 2 and Ali Shamseddine 2,* 1 Global Health Institute, American University of Beirut, Beirut 11-0236, Lebanon; [email protected] 2 Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut 11-0236, Lebanon; [email protected] (Y.H.); [email protected] (G.A.); [email protected] (Y.B.) * Correspondence: [email protected]; Tel.: +961-1-350-000 (ext. 5390) Abstract: Immunotherapy has changed the treatment paradigm in multiple solid and hematologic malignancies. However, response remains limited in a significant number of cases, with tumors de- veloping innate or acquired resistance to checkpoint inhibition. Certain “hot” or “immune-sensitive” tumors become “cold” or “immune-resistant”, with resultant tumor growth and disease progres- sion. Multiple factors are at play both at the cellular and host levels. The tumor microenvironment (TME) contributes the most to immune-resistance, with nutrient deficiency, hypoxia, acidity and different secreted inflammatory markers, all contributing to modulation of immune-metabolism and reprogramming of immune cells towards pro- or anti-inflammatory phenotypes. Both the tumor and surrounding immune cells require high amounts of glucose, amino acids and fatty acids to fulfill their energy demands. Thus, both compete over one pool of nutrients that falls short on needs, obliging cells to resort to alternative adaptive metabolic mechanisms that take part in shaping their inflammatory phenotypes. Aerobic or anaerobic glycolysis, oxidative phosphorylation, tryptophan catabolism, glutaminolysis, fatty acid synthesis or fatty acid oxidation, etc. -
Division of Analytical Laboratories
Michael SWERLOWYCZ 1 Brett FLETCHER 2, Roger JACKSON 2 1 Forensic Toxicology Laboratory, Division of Analytical Laboratories, Sydney, NSW, Australia 2 Drugs & Driving Toxicology Laboratory, Division of Analytical Laboratories, Sydney, NSW, Australia Division of Analytical Laboratories COWS ON COKE Levamisole: A livestock de-wormer in cocaine Introduction Recent DDL specimens (January 2009 onwards) were examined in Levamisole ((S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-B][1,3]thiazole) order to oBtain comparison levamisole data from a range of living has gained attention overseas suBjects. These were mostly cocaine-positive “drug/drive” in recent years as a cutting cases, as well as a numBer of fatal accident, sexual assault and agent for illicit cocaine. murder cases. Interestingly, levamisole appears to Be more common Levamisole, or ( l) -Tetramisole, in samples from living suBjects, But generally at lower concentrations is a drug used in the treatment than the coronial samples. of colon cancer, But primarily it has a veterinary use as an anthelmintic, to PrevalenceofLevamisoleinCocaine-positiveCases(DDL) control parasites in livestock. January2009-June2010 25 70 60 20 50 Levamisole in drug/drive Levamisole around the world and other police 15 40 specimens (DDL). Recently the US Drug Enforcement Administration (DEA) reported a 30 2009 – 2010 10 Percentage(%) significant increase in the prevalence of the drug. In late 2008 the DEA NumberofCases 20 found as much as 30% of illicit cocaine hydrochloride exhiBits contained Mean concentration in 5 levamisole, and By mid-2009 this figure had risen to 70%. This trend has 10 Blood = 0.035mg/L Been seen in other countries around the world and is reflected in illicit 0 0 cocaine exhiBits received By Australian laBoratories. -
Levamisole.Pdf
8/20/2018 Levamisole | UPMC Hillman Cancer Center Levamisole About This Drug Levamisole is used to treat cancer. This drug is given orally. Possible Side Effects Bone marrow depression. This is a decrease in the number of white blood cells, red blood cells, and platelets. Bone marrow depression usually occurs three to 10 days after the drug is given and may increase your risk of infection, fatigue, and bleeding. Raised, red rash on your arms, legs, back, or chest Abdominal pain or cramping Bitter taste in the mouth Decreased appetite Nausea and vomiting Drowsiness Irritability Sexual problems and reproduction concerns may occur. In men and women both, this drug may temporarily or permanently affect your ability to have children. This cannot be determined before your therapy. In men, this drug may interfere with your ability to make sperm, but it should not change your ability to have sexual relations. In women, menstrual bleeding may become irregular or stop while you are receiving this drug. Do not assume that you cannot become pregnant if you do not have a menstrual period. Women may experience signs of menopause like vaginal dryness or itching. This drug may have harmful effects on the unborn child, so effective methods of birth control should be used during your cancer treatment. genetic counseling is available to you to discuss the effect of this drug therapy on future pregnancies. In addition, a genetic counselor can review the potential risks of problems in the fetus due to this medication if an exposure during pregnancy has occurred. http://hillman.upmc.com/patients/community-support/education/chemotherapy-drugs/levamisole 1/2 8/20/2018 Levamisole | UPMC Hillman Cancer Center Treating Side Effects Ask your doctor or nurse about medication that is available to help you prevent or lessen nausea and vomiting. -
Modulating the Immune System Through Nanotechnology
Modulating the immune system through nanotechnology Tamara G. Dacobaa,b*, Ana Oliveraa,b*, Dolores Torresb, José Crecente- Campoa,b#, María José Alonsoa,b## aCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain. bDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain. *These authors contributed equally to this work. #Corresponding author e-mail address: [email protected] ##Corresponding author e-mail address: [email protected] 1 Abstract Nowadays, nanotechnology-based modulation of the immune system is presented as a cutting-edge strategy, which may lead to significant improvements in the treatment of severe diseases. In particular, efforts have been focused on the development of nanotechnology- based vaccines, which could be used for immunization or generation of tolerance. In this review, we highlight how different immune responses can be elicited by tuning nanosystems properties. In addition, we discuss specific formulation approaches designed for the development of anti-infectious and anti-autoimmune vaccines, as well as those intended to prevent the formation of antibodies against biologicals. Graphical abstract Keywords: nanotechnology; immune system; tolerance; stimulation; autoimmune disease; vaccine Highlights - Nanocarriers can be designed to target specific immune cells - Nanovaccines may help fighting diseases that are elusive to traditional vaccines - Nanocarriers can bias the immune response from humoral to cellular - Autoimmune disease treatments can be improved with nanotechnology-based approaches - The use of nanocarriers may help to avoid ADAs formation against biotherapeutics 2 1. Introduction The modulation of the immune system is the base of new and promising therapies for some of the most prevalent and/or severe diseases of our time, such as cancer, HIV, and diabetes. -
An Active Immunotherapy Combined with First-Line Weekly Paclitaxel In
An active immunotherapy combined with first-line weekly paclitaxel in metastatic breast cancer: first results of IMP321 (LAG-3Ig) as an antigen presenting cell activator in the AIPAC phase IIb trial Frédéric Triebel, CSO/CMO Precision: Breast Cancer March 7-8, 2017 Boston, MA. 1 ASX:PRR; NASDAQ:PBMD Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company’s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. -
Discriminative and Reinforcing Effects of Cocaine-Levamisole Combinations
Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2017 Discriminative and Reinforcing Effects of Cocaine-Levamisole Combinations Zachary J. Zimmermann Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Substance Abuse and Addiction Commons Recommended Citation Zimmermann, Zachary J., "Discriminative and Reinforcing Effects of Cocaine-Levamisole Combinations" (2017). Dissertations. 3120. https://scholarworks.wmich.edu/dissertations/3120 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. DISCRIMINATIVE AND REINFORCING EFFECTS OF COCAINE-LEVAMISOLE COMBINATIONS by Zachary J. Zimmermann A dissertation submitted to the Graduate College in partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2017 Dissertation Committee: Alan Poling, Ph.D., Chair Lisa Baker, Ph.D. David V. Gauvin, Ph.D. Cynthia Pietras, Ph.D. DISCRIMINATIVE AND REINFORCING EFFECTS OF COCAINE-LEVAMISOLE COMBINATIONS Zachary J. Zimmermann, Ph.D. Western Michigan University, 2017 The behavioral and neurochemical effects of cocaine are well established, and it is one of the most widely abused illicit drugs. Illicit cocaine is often adulterated with levamisole, which is an anthelmintic that was withdrawn from the U. S. market in 2000. It has been hypothesized that levamisole, unlike other common adulterants which are added as simple bulking agents, has effects of its own which may be responsible for its use as an adulterant. -
Is Chromogranin a Prohormone? Had Only a Fraction of the Pancreastatin Potency of the Peptide Characterized by Lee E
~N...:.AT.;:...U=--R.;:...E_V_O_L_.~32_5 _22_J_A_NU_A_R_Y_l_98_7 _________ NEWS ANDVIEWS-------------------'--301 Peptide function small percentage of plasma chromogranin was processed to a pancreastatin-like molecule, or if native chromogranin A Is chromogranin a prohormone? had only a fraction of the pancreastatin potency of the peptide characterized by Lee E. Eiden Tatemoto et at .. It is clearly necessary to establish that the molecule isolated by IN THE 4 December issue of Nature!, K. terminal processing signal for the forma- Tatemoto et at. is indeed the substance Tatemoto and co-workers report the tion of pancreastatin from a chromogranin found at beta-cell and D-cell receptors in sequence of a newly discovered putative A-like precursor in the rat. vivo. It will be of special interest to deter- hormone, pancreastatin, which as its There is chromogranin, as well as mine if amidation is necessary for bio name implies inhibits insulin (and soma pancreastatin, immunoreactivity in the logical activity, because amidation of tostatin) secretion from the endocrine pancreas of several species, and both poly- other biologically active peptides such as pancreas. There is a striking structural peptides are present in the brain"!', consis- enkephalins seems to oc-cur differentially similarity between pancreastatin and part tent with a precursor-product relationship in central and autonomic nervous tissue, of bovine chromogranin A, whose se between chromogranin A and pancreas- and this differential post-translational quence was recently reported in Nature by tatin. Whether or not pancreastatin is gen- modification may be relevant to different, myself and collaborators, and independ erated from chromogranin A or a chromo- as yet undiscovered hormonal functions of ently in the EMBO Journal by Benedum granin A-like precursor must await the these molecules. -
Molecular Advances in Pediatric Low-Grade Gliomas As a Model
Published OnlineFirst July 23, 2013; DOI: 10.1158/1078-0432.CCR-13-0662 Clinical Cancer CCR New Strategies Research New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model Eric Raabe1, Mark W. Kieran2, and Kenneth J. Cohen1 Abstract Pediatric low-grade gliomas (pLGG) account for more brain tumors in children than any other histologic subtype. While surgery, chemotherapy and radiation remain the mainstay of upfront treatment, recent advances in molecular interrogation of pLGG have shown a small number of recurring genetic mutations in these tumors that might be exploited therapeutically. Notable findings include abnormalities in the RAS/ MAP kinase pathway such as NF-1 loss or BRAF activation and mTOR activation. Recent identification of activating re-arrangements in c-MYB and MYBL1 in pediatric diffuse astrocytoma also provide candidates for therapeutic intervention. Targeting these molecularly identified pathways may allow for improved outcomes for patients as pediatric oncology moves into the era of biology-driven medicine. Clin Cancer Res; 19(17); 4553–8. Ó2013 AACR. Disclosure of Potential Conflicts of Interest M.W. Kieran is a consultant/advisory board member of Boehringer-Ingelheim, Incyte, Merck, Novartis, and Sanofi. No potential conflicts of interest were disclosed by the other authors. CME Staff Planners' Disclosures The members of the planning committee have no real or apparent conflict of interest to disclose. Learning Objective(s) Upon completion of this activity, the participant should have a better understanding of the molecular pathways that are active in pediatric low-grade gliomas and the biologic rationale underlying novel therapeutic strategies for children with these tumors. -
Prevalence of Levamisole in Urine Toxicology Screens Positive For
LETTERS portable, handheld ultrasound units are now available. In clinical settings, the marginal benefit of the added diagnos- 1988, Filly,2 in an editorial, called ultrasound the stetho- tic information likely does not justify the added cost of the scope of the future but was concerned about its use in un- device, the time it adds to the physical examination, or the trained hands. In 2002, Dodd3 encouraged teaching the tech- cost of false-positive and incidental findings requiring ad- nique of ultrasound usage to medical students beginning in ditional follow-up. the gross anatomy laboratory and ending in ward rounds We would like to emphasize that the potential for bring- and senior electives. In 2003, Greenbaum4 projected that ing new technology to the physical examination should not in the near future “medical students will also be buying a be viewed as a substitute for developing strong physical ex- ‘sonoscope’” in addition to a stethoscope. He envisioned amination skills. The routine physical examination remains the sonoscope as enhancing the physical examination of all part of standard practice because it is quick, cheap, and readily patients. With the advent of smaller, better-quality, and less- available. It also helps to formulate hypotheses and can al- expensive machines, and medical schools beginning to pro- low a physician to quickly rule in or out competing diag- vide technical training for their students, the use of point- noses. For the most part, the tips and maneuvers that we raised of-care ultrasound is increasing, with applications in physical in our article are simple, inexpensive, and easily mastered. -
An Overview of Anthelmintic Drugs in Ascaris Suum Intestine
Iowa State University Capstones, Theses and Creative Components Dissertations Spring 2019 An Overview of Anthelmintic Drugs in Ascaris suum Intestine Katie Tharaldson Follow this and additional works at: https://lib.dr.iastate.edu/creativecomponents Part of the Chemicals and Drugs Commons Recommended Citation Tharaldson, Katie, "An Overview of Anthelmintic Drugs in Ascaris suum Intestine" (2019). Creative Components. 262. https://lib.dr.iastate.edu/creativecomponents/262 This Creative Component is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Creative Components by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Tharaldson Overview of anthelmintic drugs and their receptors Part 1 Abstract In part 1 of this paper, I will discuss Ascaris suum and Ascaris lumbricoides. Ascaris suum acts as a model organism for Ascaris lumbricoides, a parasitic nematode that impacts roughly 1.2 billion people worldwide (de Silva et al. 2003). I will then go into the anthelmintic drugs currently being used to treat these infection, as well as the receptors they act on. In part 2 of this paper, I will discuss the research I did with levamisole, an anthelmintic drug, on nicotinic acetylcholine receptors (nAChRs) in the intestine of Ascaris suum. There were 5 control worms, as well as 5 levamisole treated worms. In the past, the nAChRs have been studied predominantly on the muscle in all nematode species. However, in previous work in the lab, although unpublished, there was promising expression of nAChRs in Ascaris suum intestine. -
Pharmacological Treatment of Patients with Mild to Moderate COVID-19: a Comprehensive Review
International Journal of Environmental Research and Public Health Review Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review Reinaldo B. Bestetti *, Rosemary Furlan-Daniel and Vinicius M. R. Silva Department of Medicine, University of Ribeirão Preto, 2201 Costabile Romano, Ribeirão Preto 14096-385, Brazil; [email protected] (R.F.-D.); [email protected] (V.M.R.S.) * Correspondence: [email protected] Abstract: Mild to moderate COVID-19 can be found in about 80% of patients. Although mortality is low, mild to moderate COVID-19 may progress to severe or even critical stages in about one week. This poses a substantial burden on the health care system, and ultimately culminates in death or incapacitation and hospitalization. Therefore, pharmacological treatment is paramount for patients with this condition, especially those with recognized risk factors to disease progression. We conducted a comprehensive review in the medical literature searching for randomized studies carried out in patients with mild to moderate COVID-19. A total of 14 randomized studies were identified, enrolling a total of 6848 patients. Nine studies (64%) were randomized, placebo-controlled trials, whereas five were open-label randomized trials (35%). We observed that Bamlanivimab and nitazoxanide reduced viral load, whereas ivermectin may have shortened time to viral clearance; Interferon Beta-1 reduced time to viral clearance and vitamin D reduced viral load; Favirapir, peginterferon, and levamisole improved clinical symptoms, whereas fluvoxamine halted disease progression; inhaled budesonide reduced the number of hospitalizations and visits to emergency departments; colchicine Citation: Bestetti, R.B.; reduced the number of deaths and hospitalizations. -
Anti-Depressant-Like Effect of Curculigoside Isolated from Curculigo Orchioides Gaertn Root
Wang et al Tropical Journal of Pharmaceutical Research October 2016; 15 (10): 2165-2172 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v15i10.15 Original Research Article Anti-depressant-like effect of curculigoside isolated from Curculigo orchioides Gaertn root Jing Wang1*, Xiao-Li Zhao2 and Lan Gao3 1Neurology Department, Shanxi Provincial People’s Hospital, Taiyuan 030012, 2Neurology Department, The First Hospital of Xi’an City, Xi’an 710002, Shanxi, 3Beijing Huilongguan Hospital, Beijing 100096, China *For correspondence: Email: [email protected]; Tel/Fax: +86-0351-4960171 Received: 5 March 2016 Revised accepted: 9 September 2016 Abstract Purpose: To investigate the anti-depressant-like activity of curculigoside from Curculigo orchioides Gaertn and its underlying mechanism(s). Methods: Antidepressant-like activity was determined in mice through forced swimming test (FST), tail suspending test (TST), and open field test (OFT). Mechanism of action was investigated by measuring levels of dopamine (DA), norepinephrine (NE), and 5-hydroxytryptamine (5-HT) in chronic mild stress (CMS) rats using high-performance liquid chromatography-electron capture detector (HPLC-ECD). Western blotting was used to investigate the effect of curculigoside on the expression of brain-derived neurotrophic factor (BDNF) protein in rats. Results: In FST and TST, treatment of mice with curculigoside (10, 20, 40 mg/kg, p.o.) significantly reduced immobility time, which was, however, unaffected by locomotor activity when assessed in the OFT. The treatment led to significant increases in DA, NE and 5-HT, and up-regulation of BDNF protein expression in the hippocampus of the CMS rats.